The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread
Condition(s):Breast NeoplasmsLast Updated:May 31, 2023Completed
Hide Studies Not Open or Pending
Condition(s):Breast NeoplasmsLast Updated:May 31, 2023Completed
Condition(s):Metastatic Breast CancerLast Updated:August 20, 2013Withdrawn
Condition(s):Metastatic Breast CancerLast Updated:February 23, 2017Completed
Condition(s):Estrogen Receptor-positive Breast Cancer; Progesterone Receptor Positive Tumor; Recurrent Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast CancerLast Updated:October 17, 2018Completed
Condition(s):Breast CancerLast Updated:April 10, 2012Terminated
Condition(s):Locally Advanced Breast Cancer; Metastatic Breast CancerLast Updated:February 24, 2015Completed
Condition(s):Breast NeoplasmsLast Updated:May 7, 2014Completed
Condition(s):Breast CancerLast Updated:August 24, 2023Recruiting
Condition(s):Breast Cancer; Stage II Breast Cancer; Stage III Breast CancerLast Updated:March 3, 2022Completed
Condition(s):Breast CancerLast Updated:June 18, 2019Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.